Anatara Lifesciences Ltd ( (AU:ANR) ) has provided an update.
Anatara Lifesciences Ltd announced a change in its board, with the resignation of non-executive director Mr. Nicholas Haslam and the appointment of Mr. Jonathan Lindh as a non-executive director. This move aligns with Anatara’s ongoing board renewal process following the GaRP-IBS trial Stage 2 analysis. Mr. Lindh, who also serves as the Company Secretary, brings extensive legal and corporate governance experience, which is expected to support the company’s strategic objectives and enhance its industry positioning.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a company focused on developing and commercializing innovative, evidence-based health products, particularly targeting gastrointestinal diseases. The company aims to address significant unmet needs in human health by building a pipeline of products that deliver real outcomes for patients and value for shareholders.
YTD Price Performance: 4.00%
Average Trading Volume: 87,500
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$11.1M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.